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Objectives: To investigate the effectiveness of riluzole in a long-term follow-up of cohort
with sporadic amyotrophic lateral sclerosis (ALS) in a real-world study.
Methods: Patients with ALS between 2007 and 2013 were followed up every
3 months. Survival and tracheotomy were predefined as primary outcome measures.
The cumulative defined daily dose (cDDD) of riluzole was estimated. The patients in the
riluzole group were classified into 1 of 3 subgroups according to the cDDD quartiles.
Survival was analyzed using Kaplan–Meier and Cox regression analysis.
Results: Of the 1,540 ALS patients, 415 (26.9%) used riluzole, and the remainder did
not. In the riluzole group, the age at onset was greater (p = 0.016), the diagnostic
delay was shorter (p < 0.0005), the body mass index (BMI) was higher (p < 0.0005),
and the scores for both the functional rating scale (FRS) and the revised FRS (FRS-R)
were higher (both p < 0.0005) than those of the control group. The median cDDD of
riluzole was 28 (2,800 mg). Although Kaplan–Meier analysis did not reveal a significant
difference between the two groups (p = 0.780), it showed that the prognosis of the
beyond quartile 3 subgroup [cDDD ≥ 168 (16,800 mg)] was significantly better than
that of the other groups [adjusted HR 0.488 (0.320–0.746), p = 0.001].
Conclusion: In China, older ALS patients and patients who had a higher BMI, shorter
diagnostic delay, and higher FRS or FRS-R scores were more likely to use riluzole. Long-
term use of riluzole was associated with a better prognosis for ALS patients, whereas
short-term use had little effect on survival.
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INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that is characterized by
the progressive degeneration of upper and lower motor neurons. The typical clinical features of
this disease include limb paralysis, muscle atrophy, dysphagia, dysarthria, shortness of breath, and
respiratory failure (Mandrioli et al., 2006; Chiò et al., 2009; Robberecht and Philips, 2013). In most
studies, the reported median survival time for ALS patients is 3–5 years, and riluzole has been
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found to be effective in improving the prognosis of ALS patients
(Mandrioli et al., 2006; Sabatelli et al., 2008; Chiò et al., 2009;
Wijesekera et al., 2009; Kiernan et al., 2011; Miller et al., 2012;
Lee et al., 2013). Because ALS treatment is not covered by medical
insurance in China and because of the high cost of riluzole, the
percentage of Chinese sporadic ALS patients using riluzole was
only approximately one third, a fraction that is much lower than
that reported in other studies (Chen et al., 2015). It is important to
determine whether riluzole is effective as a real-world treatment
for Chinese ALS patients and to improve patient counseling and
the design of clinical trials.
Compared to clinical trials in which the phenotype and
severity of a disease are narrowly defined, cohort studies, which
include patients across the full clinical spectrum of a disease,
maybe a superior “real-world” representation of the disease
(Cetin et al., 2015). Although riluzole has been used in ALS
patients for many years, its effectiveness has seldom been
confirmed in real-world studies. In this eight-year prospective,
clinic-based cohort study, we followed ALS patients of different
phenotypes and demonstrated an effect of long-term riluzole use
in our patients.
MATERIALS AND METHODS
Protocol Approvals, Registrations, and
Patient Consent
This study was approved by the institutional ethics committee
of Peking University Third Hospital (PUTH; IRB00006761). The
study group obtained written informed consent from each patient
before they participated in the study.
Subjects and Definitions
All patients with a diagnosis of ALS from January 2007 to
December 2013 were recruited, screened, and followed up every
3 months. Each patient was independently interviewed and
examined by two board-certified neurologists from the study
group who had experience with motor neuron diseases. Patients
were categorized with limb-onset ALS, bulbar-onset ALS, flail-
arm syndrome (FAS), progressive muscular atrophy (PMA), or
primary lateral sclerosis (PLS) according to the site of onset
and clinical features (Wijesekera et al., 2009; Kiernan et al.,
2011). For all cases, baseline demographic details, clinical data,
the functional rating scale (FRS) score and the revised FRS
(FRS-R) score were collected on the patient’s first visit and at
follow-up visits. Survival and tracheotomy were predefined as
primary outcome measures. Information about the use of riluzole
was acquired from hospital and pharmacy medical records and
during follow-up visits. The censoring date for the survival data
was January 31, 2015. Patients lost to follow-up were censored at
the last known living date.
Patients were diagnosed and classified according to the Airlie
House diagnostic criteria (Brooks et al., 2000). Because patients
with pure lower motor syndromes could not be classified using
these established criteria, they were classified into an additional
category of suspected ALS (Wijesekera et al., 2009). Patients
in the suspected ALS category were classified into the PMA,
limb-onset ALS or FAS categories based on their subsequent
clinical evaluations.
In the database, “Use of riluzole” was defined as treatment
with riluzole (50 mg) twice per day for longer than 2 weeks.
According to previous studies, the dose of riluzole administered
to a 70-kg adult in 1 day (100 mg) was defined as 1 defined
daily dose (DDD), which has been recommended by the World
Health Organization as a unit to use to assess the standard dose
of drug. The cumulative DDD (cDDD), which is a measure of the
duration of drug use, was estimated as the sum of the dispensed
DDD of riluzole and was analyzed with respect to ALS prognosis
(Lin et al., 2015). The patients were divided into the control
group or the riluzole group according to their use of riluzole.
In the riluzole group, the cDDD of riluzole was estimated from
the medical record of each patient. The patients in the riluzole
group were then classified into 1 of 3 subgroups according to
the cDDD: The below quartile 1 group, the quartile 1 through
3 group, or the beyond quartile 3 group. Differences between the
subgroups were also analyzed. “Lost to follow-up” was defined
as a change in the telephone number of a patient or a patient’s
refusal to participate in follow-up evaluations more than three
times. “Diagnostic delay” was defined as the time from symptom
onset to a confirmed diagnosis of ALS made by a board-certified
neurologist. “Contact with pesticides” was defined as selling,
delivering, or spraying pesticides at least one time in daily life.
“Alcohol abuse” was defined as consuming an alcoholic drink
more than twice a week for more than 1 year. Residence was
categorized as rural or urban.
Statistical Analysis
The study group collected paper copies of case report forms
from the clinic weekly. Data were double-entered and double-
checked by independent investigators. The statistical analysis was
first conducted using the total group of patients and then using
subgroups defined according to sex, phenotype, age at onset, and
dose of riluzole. All variables were analyzed using descriptive
statistics, including the mean, median, 95% confidence interval
(CI), and inter-quartile range (IQR). Significance was tested
at the 5% level, and all analyses were performed using the
SPSS V.16.0 software package (SPSS, Chicago, IL, USA). Q–Q
plots were used to determine whether the data were normally
distributed. Some data that were not normally distributed were
normalized by a log transformation. For continuous data that
were normally distributed, parametric tests [one-way analysis of
variance (ANOVA) or Student’s t-test] were used to compare
subgroups, and for categorical variables, non-parametric tests
(χ2 test, Fisher’s exact test, Kruskal–Wallis one-way ANOVA
by ranks, or Mann–Whitney U test) were used. Kaplan–Meier
analysis was used to describe the survival curve. Covariates were
analyzed using the log-rank test and Cox regression analysis.
When the survival times of patients with the different phenotypes
were examined, the PLS group was excluded from the survival
analysis because no patients in that group had died. FRS and FRS-
R scores were collected on the first visit and at every follow-up
visits, but only the first FRS and FRS-R scores were used in the
analysis as the baseline score and as a factor of prognosis in the
Cox regression model.
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RESULTS
During the study period, 1,540 individual sporadic ALS patients
were identified. Of these, 1,125 (73.1%) patients were in the
control group, and 415 (26.9%) patients were in the riluzole
group. The characteristics of the different groups are shown in
Table 1. Till January 31, 2015, 662 patients reached the end
point and 157 were in the riluzole group. The percentage of
patients who reached the end point was higher in the control
group (44.9%) than in the riluzole group (37.8%; p= 0.015). The
percentage of patients who lived in an urban area was higher
in the riluzole group (70.9%) than in the control group (60.3%;
p < 0.0005). Spearman correlation analysis revealed that living
in a rural area was correlated with lower FRS (rp = −0.072,
p= 0.016) and FRS-R scores (rp =−0.071, p= 0.018).
Subgroup Analyses
Subgroups Based on Riluzole cDDD
In the riluzole group, the cDDD of one quartile was 28
(2,800 mg), and the cDDD of three quartiles was 168 (16,800 mg).
There were 182 patients in the below quartile 1 group, 118
patients in the quartile 1 through 3 group, and 115 patients
in the beyond quartile 3 group. The mean age at onset was
50.6 years old in the below quartile 1 group (95% CI 48.9–
52.3), 51.8 years old in the quartile 1 through 3 group (95% CI
49.7–53.9), and 51.3 years old in the beyond quartile 3 group
(95% CI 49.1–53.5). The mean age at onset did not significantly
differ between the subgroups (p = 0.659). The M:F ratio was
1.49:1 in the below quartile 1 group, 1.51:1 in the 1 through 3
group, and 1.67:1 in the beyond quartile 3 group. Differences in
the M:F ratio between the three subgroups were not significant
(p = 0.902). The body mass index (BMI) of the beyond quartile
3 group [23.8 kg/m2 (95% CI 23.2–24.3)] was higher than that
of the quartile 1 through 3 group [22.9 kg/m2 (95% CI 22.3–
23.5)], but pair-wise comparisons between the other subgroups
did not reveal significant differences. The median diagnostic
delay did not significantly differ between the three subgroups
[the below quartile 1 group, 11.0 months (IQR 10); the quartile
1 through 3 group, 11.0 months (IQR 7.75); the beyond quartile
3 group, 12.0 months (IQR 11.75)] (p = 0.160). The median
FRS score was 34.0 (IQR 6) in the below quartile 1 group,
34.5 (IQR 7) in the quartile 1 through 3 group, and 34.0
(IQR 7) in the beyond quartile 3 group. Neither the FRS score
(p= 0.733) nor the FRS-R score differed between the groups [the
below quartile 1 group, 42.0 (IQR 6); the quartile 1 through 3
group, 42.0 (IQR 8), the beyond quartile 3 group, 42.0 (IQR 7)]
(p= 0.730).
Gender-Based Subgroups
Among the male patients, 252 (26.0%) used riluzole, and 718
(74.0%) did not. The mean age at onset of the riluzole group was
52.0 years old (95% CI, 50.6–53.4), which was significantly older
than that of the control group [49.8 years old (95% CI, 49.0–50.7)]
(p = 0.011). The BMI of the riluzole group [23.4 kg/m2 (95% CI,
23.1–23.8)] was significantly higher than that of the control group
[22.6 kg/m2 (95% CI, 22.3–22.9)] in the male patients (p= 0.001).
The median diagnostic delay was 14.0 months (IQR 15.0), and the
difference between the riluzole group and the control group was
also significant [riluzole group, 10.5 months (IQR 9.0); control
group, 16.0 months (IQR 17.0)] (p< 0.0005). The FRS [34.0 (IQR
7.0)] and FRS-R scores [42.0 (IQR 7.0)] of the riluzole group
were higher than those of the control group [FRS, 33.0 (IQR 8.0),
p= 0.004; FRS-R, 41.0 (IQR 8.0), p= 0.002].
Among the female patients, 163 (28.6%) used riluzole, and 407
(71.4%) did not. The mean age at onset in the control [48.9 years
TABLE 1 | Demographics of Chinese sporadic ALS patients who did or did not use riluzole.
Patients who used riluzole Patients who did not use riluzole p-value
Number of patients (%) 415 (26.9) 1125 (73.1)
Age at onset [mean (95% CI), years] 51.1 (50.0–52.2) 49.5 (48.8–50.2) 0.016
Gender ratio (M:F) 1.55:1 1.76:1 0.284
% of cases of different phenotypes 0.036
Limb-onset ALS 77.1 71.0
Bulbar-onset ALS 15.9 16.5
FAS 4.8 8.6
PMA 1.9 3.0
PLS 0.2 0.8
Diagnostic delay [median inter-quartile
range (IQR), months]
11.0 (11.0) 15.0 (17.0) <0.0005
BMI [mean (95% CI), kg/m2] 23.3 (23.0–23.6) 22.6 (22.4–22.9) <0.0005
% of cases that reached a categorization of
laboratory-supported probable at presentation
81.0 74.9 0.015
Functional rating scale (FRS) score
[median (IQR)]
34.0 (7.0) 32.0 (9.0) <0.0005
Revised FRS (FRS-R) score [median
(IQR)]
42.0 (7.0) 40.0 (9.0) <0.0005
ALS, amyotrophic lateral sclerosis; FAS, flail arm syndrome; PMA, progressive muscular atrophy; PLS, primary lateral sclerosis; BMI, body mass index; CI, confidence
interval.
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old (95% CI, 47.7–50.1)] and riluzole groups [49.8 years old
(95% CI, 48.0–51.6)] did not significantly differ (p = 0.425).
There were no significant differences in BMI between the riluzole
group [23.0 kg/m2 (95% CI, 22.5–23.5)] and the control group
[22.6 kg/m2 (95% CI, 22.2–23.0)] (p = 0.274). The median
diagnostic delay of the female patients was 14.0 months (IQR
15.0), and the difference between the riluzole group and the
control group was significant [riluzole group, 12.0 months (IQR
12.0); control group, 15.0 months (IQR 16.0)] (p < 0.0005). The
FRS [34.0 (IQR 7.0)] and FRS-R scores [42.0 (IQR 8.0)] of the
riluzole group were higher than those of the control group [FRS,
31.0 (IQR 10.0), p< 0.0005; FRS-R, 39.0 (IQR 10.0), p< 0.0005].
Phenotype-Based Subgroups
The percentage of patients who used riluzole was 28.6%
(320/1,118) in the limb-onset ALS, 26.2% (66/252) in the bulbar-
onset ALS, 17.1% (20/117) in the FAS, and 19.0% (8/42) in
the PMA. The proportion of riluzole users was not significantly
different between the limb-onset ALS and the bulbar-onset ALS
(p = 0.244), but it was higher in limb-onset ALS than in the
FAS and PMA. There were ten patients in the PLS, and only
one used riluzole. The proportion of riluzole users significantly
differed between the phenotypes (p = 0.036). The age at onset
was significantly greater in the riluzole group [49.9 years old (95%
CI, 48.6–51.1)] than in the control group [48.3 years old (95% CI,
47.5–49.1)] only in the limb-onset ALS (p= 0.036). Differences in
BMI were observed only in the bulbar-onset ALS (riluzole group,
23.03 kg/m2; control group, 21.79 kg/m2; p = 0.011) and the
PMA (riluzole group, 25.11 kg/m2; control group, 21.82 kg/m2;
p = 0.030). Compared with the diagnostic delay of the control
group, that in the riluzole group was significantly shorter when
this parameter was analyzed in the limb-onset ALS [riluzole
group, 11.0 months (IQR 10.0); control group, 15.0 months
(IQR 16.0); p < 0.0005], the bulbar-onset ALS [riluzole group,
10.0 months (IQR 8.0); control group, 13.0 months (IQR 12.0);
p < 0.0005], and the FAS [riluzole group, 12.0 months (IQR
14.75); control group, 18.0 months (IQR 27.0); p = 0.028]. The
FRS and FRS-R scores were higher in the riluzole group than
in the control group in the limb-onset ALS (FRS, p = 0.002;
FRS-R, p = 0.001), bulbar-onset ALS (FRS, p < 0.0005; FRS-R,
p< 0.0005), and FAS (FRS, p= 0.010; FRS-R, p= 0.010).
Age-Based Subgroups
In order to analyze the difference between riluzole and control
groups in different age groups, we divided the patients into
three age groups according to the quartiles of age at onset: Age
<42.0 years old group, age between 42.0 and 58.0 years old group,
and age ≥58.0 years old group. The percentage of patients who
used riluzole was 26.1% (96/368) in the age <42.0 years old
group, 23.9% (177/740) in the age between 42.0 and 58.0 years
old group, and 32.9% (142/432) in the age≥58.0 years old group.
The proportion of patients who used riluzole was significantly
different between the age groups (p = 0.004). There was no
significant difference in the M:F ratio of the riluzole group and
the control group in all the three age groups (in age <42.0 years
old group: Riluzole group 1.2 vs. control group 1.5, p = 0.194;
in age between 42.0 and 58.0 years old group: Riluzole group 1.9
vs. control group 1.6, p = 0.244; in age ≥58.0 years old group:
Riluzole group 1.8 vs. control group 1.7, p = 0.452). The BMI
of the riluzole group was significantly higher than that of the
control group in the age between 42.0 and 58.0 years old group
[riluzole group, 23.5 kg/m2 (95%CI 23.1–24.0); control group,
22.8 kg/m2 (95%CI 22.5–23.2); p = 0.016] and age ≥58.0 years
old group [riluzole group, 23.0 kg/m2 (95%CI 22.5–23.6); control
group 22.3 kg/m2 (95%CI 21.9–22.8); p = 0.016]. The median
diagnostic delay time in the riluzole group was shorter than in
the control group in all three age groups [in age <42.0 years
old group: Riluzole group, 12.0 months (IQR 11.0) vs. control
group, 16.0 months (IQR 21.75); in age between 42.0 and
58.0 years old group: Riluzole group, 11.0 months (IQR 10.75)
vs. control group, 15.0 months (IQR 17.0); in age ≥58.0 years
old group: Riluzole group, 10.0 months (IQR 9.0) vs. control
group, 15.0 months (IQR 13.25); all p< 0.0005]. The proportions
of different phenotypes in the riluzole and the control groups
did not show significant difference in all the three age groups
(in age <42.0 years old group, p = 0.405; in age between 42.0
and 58.0 years old group, p = 0.116; in age ≥58.0 years old
group, p = 0.592). The FRS and FRS-R scores of the riluzole
group were significantly higher in the age between 42.0 and
58.0 years old group [FRS: Riluzole group, 34.0 (IQR 6.0) vs.
control group, 32.0 (IQR 9.0); FRS-R: Riluzole group, 42.0 (IQR
7.0) vs. control group, FRS-R 40.0 (IQR 10.0); both p < 0.0005]
and age ≥58.0 years old group [FRS: Riluzole group, 34.0 (IQR
6.0) vs. control group, 32.0 (IQR 8.0), p = 0.005; FRS-R: Riluzole
group, 42.0 (IQR 7.0) vs. control group, FRS-R 39.0 (IQR 8.0),
p= 0.003].
Factors Associated with Survival
The Kaplan–Meier analysis did not reveal any significant
differences in the median survival time of the riluzole group
[67.0 months (95% CI 54.7–79.3)] and the control group
[64.0 months (95% CI 57.8–70.2)] (p = 0.780). However, when
the prognosis of the subgroups in the riluzole group and
the control group were compared, the survival of the beyond
quartile 3 subgroup was significantly better than that of the
other groups (compared with the control group, p = 0.001;
compared with the below quartile 1 subgroup, p = 0.001;
compared with the quartile 1 through 3 subgroup, p < 0.0005)
(Figure 1).
Among the male patients, the median survival time of the
riluzole group was 58.0 months (95% CI 46.0–70.0), which
did not significantly differ with that of the control group
[61.0 months (95% CI 54.3–67.7)] (p= 0.395). Subgroup analysis
showed that the median survival time of the beyond quartile
3 group was 88.0 months, which was much longer than that
of the other subgroups as well as the control group [below
quartile 1 group, 55.0 months (95% CI 43.6–66.4), p < 0.0005;
quartile 1 through 3 group, 41.0 months (95% CI 32.3–49.7),
p < 0.0005; control group, 61.0 months (95% CI 54.3–67.7),
p = 0.006]. Among the female patients, the survival times of the
riluzole group and the control group did not significantly differ
(p = 0.192). Subgroup analysis showed that the median survival
time also did not differ between the subgroups and the control
group (p= 0.338).
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FIGURE 1 | Kaplan-Meier survival curves. (A) Survival analysis stratified by riluzole; (B) Survival analysis stratified by quartiles of dose of riluzole.
Because there were not enough cases in the PLS group,
the PLS phenotype was excluded from the analysis of different
phenotypes. The survival times of the riluzole group and
the control group did not significantly differ in any of the
phenotypes (limb-onset ALS, p = 0.890; bulbar-onset ALS,
p = 0.788; FAS, p = 0.548; PMA, p = 0.964). However, analysis
of the survival of the different cDDD subgroups within the
phenotypes showed that the survival of the beyond quartile 3
group was significantly better than that of the other groups only
for patients with limb-onset ALS (compared with the control
group, p = 0.002; compared with the below quartile 1 group,
p = 0.001; compared with the quartile 1 through 3 group,
p< 0.0005).
In the age between 42.0 and 58.0 years old group, median
survival was prolonged by 24.0 months (the riluzole group,
83.0 months; the control group, 59.0 months; p = 0.024), while
in other two age groups there was no significant difference in
survival between the riluzole group and the control group. In
subgroup analysis of cDDD, the prognosis of the beyond quartile
3 group was significantly better than that of the other groups in
the age between 42.0 and 58.0 years old group (compared with
the control group, p= 0.003; compared with the below quartile 1
group, p = 0.017; compared with the quartile 1 through 3 group,
p = 0.114) and in the age ≥58.0 years old group (compared with
the control group, p= 0.062; compared with the below quartile 1
group, p = 0.001; compared with the quartile 1 through 3 group,
p = 0.004), and was better than that of the quartile 1 through 3
group in the age <42.0 years old group (p= 0.002).
In the univariate analysis, the factors related with survival
included age at onset [HR 1.044 (1.037–1.052), p < 0.0005],
gender [female compared with male, HR 0.826 (0.699–0.975),
p = 0.024], BMI [HR 0.936 (0.908–0.965), p < 0.0005],
diagnostic delay [HR 0.955 (0.949–0.975), p < 0.0005], Airlie
House category at presentation [compared with definite ALS:
Probable ALS supported by laboratory findings, HR 0.743 (0.562–
0.981), p = 0.036; others were not significant], phenotype
[compared with limb-onset ALS: bulbar-onset ALS, HR 1.448
(1.178–1.779), p < 0.0005; others were not significant], contact
history with pesticides [HR 1.322 (1.033–1.692), p = 0.027],
and FRS score [HR 0.975 (0.962–0.988), p < 0.0005]. In the
multivariate Cox regression model, after adjusting for age,
gender, BMI, diagnostic delay, phenotype, Airlie House category
at presentation, residence, FRS score, history of smoking or
alcohol abuse, and contact history with pesticides, there was
no significant difference in survival time between the riluzole
group and the control group [adjusted HR 0.855 (0.685–1.068),
p = 0.167]. However, after adjusting for the factors mentioned
above, the subgroup analysis showed that the prognosis of the
beyond quartile 3 subgroup was significantly better than that of
the control group [adjusted HR 0.488 (0.320–0.746), p = 0.001],
indicating that the long-term use of riluzole could improve ALS
patient survival. Older age at onset, male gender, lower BMI,
shorter diagnostic delay from symptom onset, residence in a rural
area, and lower FRS score at presentation were also related to
poorer ALS patient prognosis in the multivariate Cox regression
model (Figure 2).
DISCUSSION
In this study, although the prognosis of the riluzole group and
the control group did not significantly differ, the prognosis of
the beyond quartile 3 subgroup was much better than that of the
other groups even after adjusting for other factors. This result
suggests that the long-term use of riluzole may improve the
prognosis of ALS patients.
Our data showed that older patients and patients who lived
in urban areas and who had a higher BMI, shorter diagnostic
delay, higher diagnostic category at presentation, and a higher
FRS or FRS-R score were more likely to use riluzole. Based on
this result, we can divide the patients who used riluzole into
two situations. First, the faster the disease progressed or the
more severe the disease, the more willing the patients were to
use riluzole. In previous studies, greater age at onset, shorter
diagnostic delay from symptom onset and higher diagnostic
category at presentation were all related to poorer survival and
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FIGURE 2 | Survival curves after adjusting for age, gender, BMI, diagnostic delay time, phenotype, Airlie House category at presentation, residence,
FRS score, history of smoking or alcohol abuse, contact history of harmful gas or pesticides at the covariate means using Cox regression model.
(A) Survival analysis stratified by riluzole; (B) Survival analysis stratified by quartiles of dose of riluzole.
faster disease progression (Chiò et al., 2009; Chen et al., 2015).
However, the shorter diagnostic delay may also be explained
by the fact that those who subsequently take riluzole are more
motivated to visit the hospital than those who do not (Roche
et al., 2012). Second, because a higher BMI and residence in an
urban area may be related to better economic conditions, the
affordability of the medication for the patients may influence
riluzole use. Because residence in a rural area was related to lower
FRS and FRS-R scores, the lower FRS and FRS-R scores of the
control group may be explained by the greater percentage of
patients who lived in a rural area in this group. Because China
is still a developing country, there are a large income differences
between urban and rural areas, and because ALS treatment is not
covered by medical insurance in China, the finding that fewer
patients who lived in rural areas could afford the expense of
riluzole can be easily explained.
In most previous studies about the prognosis of ALS, riluzole
was analyzed as a survival factor, but its daily and cumulative
dose has seldom been taken into consideration (Chiò et al., 2002,
2009; Traynor et al., 2003; Kiernan et al., 2011; Lee et al., 2013;
Chen et al., 2015). In the prognostic studies, the effect of riluzole
on the survival of ALS patients was controversial: Most of the
studies found it was related to longer survival, but in our previous
study we did not find this tendency (Chen et al., 2015). In a
meta-analysis that included four randomized trials of riluzole in a
total of 1,477 people with ALS, when the two trials that recruited
a homogeneous group of participants were analyzed, riluzole
had a significant effect on survival (p = 0.039). However, when
the third trial that involved more seriously affected and older
patients was included in the analysis, the treatment effect was
not significant (p = 0.056; Miller et al., 2012). Some researchers
suggested that riluzole could only slow down and not reverse the
degeneration of motor neurons and was therefore less effective
in advanced-stage patients (Traynor et al., 2003). Because the age
at onset and disease severity are more heterogeneous in a real-
world cohort study than in randomized trials, the finding that the
prognosis of riluzole group was not better than that of the control
group may explained by the fact that older and more severely
affected patients were included in the cohort study. However, our
subgroup analysis did show that the beyond quartile 3 subgroup
(16,800 mg) had a much better prognosis than other groups,
even after adjusting for all other factors. Because the DDD of
riluzole was 100 mg per day, it appears that the use of riluzole
over approximately 6 months may improve ALS patient survival.
It was notable that the effect of long-term riluzole use was
found only in the male patients, whereas in the female patients,
no significant differences in survival were found between the
subgroups. In our previous study, we also found that the male and
female patients differed in many aspects, such as the age at onset,
survival time, and the prognosis of the different phenotypes.
Some investigators have argued that these difference may be
explained by metabolic and hormonal differences between males
and females (Aksoy et al., 2014; Chen et al., 2015). Because
riluzole could only slow down the progression of the disease
rather than reverse it, (Traynor et al., 2003) the reduced
effectiveness of long-term riluzole use in the female patients may
be explained by the significantly longer survival time of female
ALS patients, which means the disease itself progresses much
more slowly in females than in males.
The lower percentage of riluzole users in the FAS group may
be explained by the slower progression of the disease (Chen
et al., 2015). The fact that the better prognosis of the beyond
quartile 3 group was only observed in the limb-onset ALS group
suggests that the mechanism of and response to riluzole differ
between the phenotypes. In the first clinical trial of riluzole in
1994, researchers found that riluzole seemed to be more effective
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in bulbar-onset ALS patients (Bensimon et al., 1994). However,
the larger and subsequent clinical trial showed that the difference
in the effect of riluzole treatment between bulbar-onset and limb-
onset ALS patients might be an artifact of the small sample size
of the previous study (Lacomblez et al., 1996). It is interesting
that in a population-based study of the Italian patients, riluzole
was effective in bulbar-onset ALS patients but had no effect on
survival at 12 months in limb-onset ALS patients (Zoccolella
et al., 2007). In another population-based study in the Irish
people, researchers also found that the bulbar-onset ALS patients
benefited more from riluzole treatment, although the reason for
this was unknown (Traynor et al., 2003). In our study, however,
although the proportion of patients using riluzole showed to be
similar in bulbar-onset and limb-onset patients, the prognosis
of the riluzole users seemed to be better only in the limb-
onset patients. In our previous study, we found that the clinical
characteristics of Chinese ALS patients were quite different from
that of European and North American patients, and the different
effect of riluzole in bulbar-onset and limb-onset patients might
also suggest the fact that the features of ALS patients in China
are unique (Chen et al., 2015; Huynh and Kiernan, 2015).
However, the small sample size for some phenotypes may also
have influenced the results of the comparisons.
In the study of Zoccolella et al. (2007) older patients (patients
aged > 70 years) benefited more from the treatment of riluzole .
In our study, there were only 57 patients older than 70 years old
and there was no significant difference in survival between the
riluzole and the control group in patients older than 70 years old
(32 months for the riluzole group vs. 27 months for the control
group; p = 0.298). The mean age at onset of ALS patients in
China was much younger than that in other countries and the
proportion of ALS patients older than 70 years old was much
lower than that in Italian (26.1% in Italian patients vs. 3.7%
in Chinese patients; Zoccolella et al., 2007; Chen et al., 2015).
However, when we divided patients into three groups according
to the quartiles of age at onset, median survival was prolonged
by 24 months because of the treatment of riluzole in the age
between 42.0 and 58.0 years old group, while in age <42.0 and
≥58.0 years old group there was no significant difference in
survival between the riluzole group and the control group. In
the subgroup analysis, a cDDD of 16,800 mg (about 6-month
use) were effective both in the age between 42.0 and 58.0 years
old group and in the age ≥58.0 years old group. This result
suggests that long-term use of riluzole (cDDD ≥ 16,800 mg)
may improve the prognosis of older patients (aged ≥ 42.0 years)
and this proved the findings of Zoccolella et al. (2007), although
the definition of “older patients” in our study was much
younger.
Our study has several limitations. First, although the patients’
use of riluzole was acquired from the hospital and pharmacy
medical records as well as from follow-up visits, the number of
patients who used riluzole could still have been underestimated.
Second, some important data, such as gastrostomy data, the use
of other medicine and respiratory status, were absent from our
database; the lack of these data could have influenced the data
analysis. Third, since the cDDD would be bigger if the patient
lived longer, it might be a potential confounder of the dose-
dependent effect of riluzole on survival. However, the median
survival time of Chinese ALS patients was 71 months (Chen et al.,
2015), so a cDDD of 16,800 mg (about 6-month use) might not
sufficiently reflect a longer survival of patients. Fourth, due to the
limitations of a single-center clinic cohort study, the results may
differ from those of a population-based study. The validity of our
observations based on this clinical database is strengthened by
the findings from a population-based study in Taiwan in which
the demographic and clinical features were quite consistent with
our data (Lee et al., 2013). Since the importance of population-
based studies in defining clinical features and prognostic factors
in ALS (Beghi et al., 2006; Logroscino et al., 2008), a nationwide
multicenter study or population-based study for Chinese patients
should be conducted in the future (Zoccolella et al., 2008; Chen
et al., 2015).
In summary, this study showed that in China, older ALS
patients and patients who had a higher BMI, shorter diagnostic
delay, and higher FRS or FRS-R scores were more likely to use
riluzole. The long-term [cDDD≥ 168 (16,800 mg)] use of riluzole
was associated with a better prognosis for ALS patients, whereas
short-term use had little effect on survival.
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